Arjo AB (publ) (ARJO-B) - Total Liabilities
Based on the latest financial reports, Arjo AB (publ) (ARJO-B) has total liabilities worth Skr7.52 Billion SEK (≈ $809.27 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arjo AB (publ) - Total Liabilities Trend (2013–2025)
This chart illustrates how Arjo AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See ARJO-B current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Arjo AB (publ) Competitors by Total Liabilities
The table below lists competitors of Arjo AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aubay Société Anonyme
PA:AUB
|
France | €277.79 Million |
|
Runner Xiamen Corp
SHG:603408
|
China | CN¥2.06 Billion |
|
JNTC Co. Ltd
KQ:204270
|
Korea | ₩300.47 Billion |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581
|
China | CN¥127.24 Million |
|
Yunnan Yunwei Co Ltd Class A
SHG:600725
|
China | CN¥96.71 Million |
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
USA | $39.41 Million |
|
Kim Loong Resources Bhd
KLSE:5027
|
Malaysia | RM414.07 Million |
|
Henan Taloph Pharmaceutical Stock Co Ltd
SHG:600222
|
China | CN¥2.01 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Arjo AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Arjo AB (publ) (ARJO-B) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arjo AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arjo AB (publ) (2013–2025)
The table below shows the annual total liabilities of Arjo AB (publ) from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr7.52 Billion ≈ $809.27 Million |
-5.27% |
| 2024-12-31 | Skr7.94 Billion ≈ $854.26 Million |
-5.74% |
| 2023-12-31 | Skr8.42 Billion ≈ $906.23 Million |
-1.43% |
| 2022-12-31 | Skr8.54 Billion ≈ $919.36 Million |
+10.56% |
| 2021-12-31 | Skr7.73 Billion ≈ $831.55 Million |
-6.09% |
| 2020-12-31 | Skr8.23 Billion ≈ $885.46 Million |
-3.29% |
| 2019-12-31 | Skr8.51 Billion ≈ $915.60 Million |
+10.36% |
| 2018-12-31 | Skr7.71 Billion ≈ $829.61 Million |
+8.03% |
| 2017-12-31 | Skr7.14 Billion ≈ $767.95 Million |
+75.98% |
| 2016-12-31 | Skr4.05 Billion ≈ $436.38 Million |
+6.99% |
| 2015-12-31 | Skr3.79 Billion ≈ $407.86 Million |
-10.19% |
| 2014-12-31 | Skr4.22 Billion ≈ $454.14 Million |
+7.54% |
| 2013-12-31 | Skr3.92 Billion ≈ $422.29 Million |
-- |
About Arjo AB (publ)
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, prevention of deep vein thrombosis and treatment of edema, leg ulcer treatment and pr… Read more